Response

Donald P. Tashkin; Stephen Rennard; J. Taylor Hays; Wendy Ma; David Lawrence; Theodore C. Lee

doi:10.1378/chest.10-3032

Response

Donald P. Tashkin, Stephen Rennard, J. Taylor Hays, Wendy Ma, David Lawrence, Theodore C. Lee

General Internal Medicine

Research output: Contribution to journal › Letter › peer-review

Original language	English (US)
Pages (from-to)	969-970
Number of pages	2
Journal	Chest
Volume	139
Issue number	4
DOIs	https://doi.org/10.1378/chest.10-3032
State	Published - Apr 2011

ASJC Scopus subject areas

Pulmonary and Respiratory Medicine
Critical Care and Intensive Care Medicine
Cardiology and Cardiovascular Medicine

Access to Document

10.1378/chest.10-3032

Cite this

@article{40c3a176954a4254850df9b0502d4d23,

title = "Response",

author = "Tashkin, {Donald P.} and Stephen Rennard and Hays, {J. Taylor} and Wendy Ma and David Lawrence and Lee, {Theodore C.}",

note = "Funding Information: Financial/nonfinancial disclosures: The authors have reported to the CHEST the following conflicts of interest: Dr Tashkin received grant support from Pfizer Inc and Nabi Pharmaceuticals and fees for attending advisory board meetings from Pfizer Inc. Dr Hays received a research grant from Pfizer Inc for the conduct of the clinical trial described in this manuscript. In the past 3 years, Dr Rennard has been a consultant or a member of an advisory board for Able Associates, Adelphi Research, Almirall/Prescott, APT Pharma/Britnall, Aradigm, AstraZeneca, Boehringer Ingelheim, Chiesi, CommonHealth, Consult Complete, COPDForum, Data-Monitor, Decision Resources, Defined Health, Dey, Dunn Group, Eaton Associates, Equinox, Gerson, GlaxoSmithKline, Infomed, KOL Connection, M Pankove, MedaCorp, MDRx Financial, Mpex, Novartis, Nycomed, Oriel Therapeutics, Otsuka, Pennside Partners, Pfizer Inc (varenicline), Pharma Ventures, Pharmaxis, Price Waterhouse, Propagate, Pulmatrix, Reckner Associates, Recruiting Resources, Roche, Schlesinger Medical, SciMed, Sudler and Hennessey, TargeGen, Theravance, UBC, Uptake Medical, and VantagePoint Management. Dr Rennard has lectured for the American Thoracic Society, AstraZeneca, Boehringer Ingelheim, California Allergy Society, Creative Educational Concept, France Foundation, Information TV, Network for Continuing Education, Novartis, Pfizer, and SOMA and has received industry-sponsored grants from AstraZeneca, Biomarck, Centocor, Mpex, Nabi Pharmaceuticals, Novartis, and Otsuka. Ms Ma is an employee of Pfizer Inc, owns Pfizer stock, and has Pfizer stock options. Dr Lawrence is an employee of Pfizer Inc, owns Pfizer stock, and has Pfizer stock options. Dr Lee is an employee of Pfizer Inc, owns Pfizer stock, and has Pfizer stock options. Funding Information: Funding/Support: This study was funded by Pfizer Inc. ",

year = "2011",

month = apr,

doi = "10.1378/chest.10-3032",

language = "English (US)",

volume = "139",

pages = "969--970",

journal = "Chest",

issn = "0012-3692",

publisher = "American College of Chest Physicians",

number = "4",

}

TY - JOUR

T1 - Response

AU - Tashkin, Donald P.

AU - Rennard, Stephen

AU - Hays, J. Taylor

AU - Ma, Wendy

AU - Lawrence, David

AU - Lee, Theodore C.

N1 - Funding Information: Financial/nonfinancial disclosures: The authors have reported to the CHEST the following conflicts of interest: Dr Tashkin received grant support from Pfizer Inc and Nabi Pharmaceuticals and fees for attending advisory board meetings from Pfizer Inc. Dr Hays received a research grant from Pfizer Inc for the conduct of the clinical trial described in this manuscript. In the past 3 years, Dr Rennard has been a consultant or a member of an advisory board for Able Associates, Adelphi Research, Almirall/Prescott, APT Pharma/Britnall, Aradigm, AstraZeneca, Boehringer Ingelheim, Chiesi, CommonHealth, Consult Complete, COPDForum, Data-Monitor, Decision Resources, Defined Health, Dey, Dunn Group, Eaton Associates, Equinox, Gerson, GlaxoSmithKline, Infomed, KOL Connection, M Pankove, MedaCorp, MDRx Financial, Mpex, Novartis, Nycomed, Oriel Therapeutics, Otsuka, Pennside Partners, Pfizer Inc (varenicline), Pharma Ventures, Pharmaxis, Price Waterhouse, Propagate, Pulmatrix, Reckner Associates, Recruiting Resources, Roche, Schlesinger Medical, SciMed, Sudler and Hennessey, TargeGen, Theravance, UBC, Uptake Medical, and VantagePoint Management. Dr Rennard has lectured for the American Thoracic Society, AstraZeneca, Boehringer Ingelheim, California Allergy Society, Creative Educational Concept, France Foundation, Information TV, Network for Continuing Education, Novartis, Pfizer, and SOMA and has received industry-sponsored grants from AstraZeneca, Biomarck, Centocor, Mpex, Nabi Pharmaceuticals, Novartis, and Otsuka. Ms Ma is an employee of Pfizer Inc, owns Pfizer stock, and has Pfizer stock options. Dr Lawrence is an employee of Pfizer Inc, owns Pfizer stock, and has Pfizer stock options. Dr Lee is an employee of Pfizer Inc, owns Pfizer stock, and has Pfizer stock options. Funding Information: Funding/Support: This study was funded by Pfizer Inc.

PY - 2011/4

Y1 - 2011/4

UR - http://www.scopus.com/inward/record.url?scp=79953759472&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=79953759472&partnerID=8YFLogxK

U2 - 10.1378/chest.10-3032

DO - 10.1378/chest.10-3032

M3 - Letter

AN - SCOPUS:79953759472

SN - 0012-3692

VL - 139

SP - 969

EP - 970

JO - Chest

JF - Chest

IS - 4

ER -

Response

ASJC Scopus subject areas

Access to Document

Other files and links

Cite this